NKTR 223

Drug Profile

NKTR 223

Alternative Names: NKTR-223

Latest Information Update: 19 Nov 2013

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class Peptides; Polymers
  • Mechanism of Action Cell membrane permeability modulators; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 19 Nov 2013 Preclinical trials in Gram-negative infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top